7 Powerful MDR 2017 Amendments in 2026: Essential Guide for Medical Device Companies

The MDR 2017 Amendments in 2026 are important for medical device manufacturers, importers, authorised agents, and other stakeholders operating in India’s medical-device sector. The Central Government has issued multiple notifications and draft notifications during 2026 concerning the Medical Devices Rules, 2017

These developments cover areas such as quality management systems, sterilization activities, labelling requirements, testing fees, and regulatory requirements for medical 

devices. Companies should therefore review their existing documentation and compliance procedures against the latest applicable requirements. 

The purpose of this guide is to explain the MDR 2017 Amendments in 2026 in simple language and help medical device businesses understand the areas that may require attention.

What Are the MDR 2017 Amendments in 2026?

The MDR 2017 Amendments in 2026 refer to amendments and regulatory developments issued during 2026 that modify or clarify provisions connected with the Medical Devices Rules, 2017.

The CDSCO’s official Gazette notification records several 2026 developments affecting MDR 2017. For example, the Medical Devices (Third Amendment) Rules, 2026 were notified on 14 August 2026 and introduced changes relating to requirements under the rules. 

CDSCO’s Gazette notification page also lists 2026 notifications concerning sterilization activities and labelling, as well as amendments and draft amendments relating to medical-device testing and other MDR provisions. 

This means medical-device companies should not treat MDR 2017 as a static regulatory framework. They should regularly monitor official CDSCO notifications and assess whether new requirements apply to their products or operations.

Why Are the MDR 2017 Amendments in 2026 Important?

The MDR 2017 Amendments in 2026 are relevant because compliance requirements can affect how medical devices are manufactured, tested, labelled, documented, and placed on the Indian market.

A regulatory change may require a company to review:

• Quality Management System documentation
• Product technical documentation
• Manufacturing procedures
• Sterilization processes
• Product labelling
• Testing arrangements
• Regulatory applications
• Risk classification
• Post-approval compliance
• Records maintained by the manufacturer

For companies planning a new CDSCO application, understanding the current regulatory position before submitting an application can also help reduce avoidable documentation issues.

7 Key MDR 2017 Amendments in 2026

1. Quality Management System Requirements for Certain Class A Devices

One notable development under the MDR 2017 Amendments in 2026 concerns Quality Management System requirements for certain Class A non-sterile and non-measuring medical devices.

The August 2026 amendment concerning Rule 63 inserted “quality management system” alongside standards in the relevant provision. The notification also states that these rules came into force from the date of their final publication in the Official Gazette. 

What Does This Mean for Companies?

Companies dealing with affected devices should review their quality-system documentation and determine whether the amended requirement applies to their particular products and activities.

Businesses should avoid assuming that Class A status automatically means every quality-related regulatory requirement is unnecessary.

2. New Sterilization-Related Requirements

Another important area in the MDR 2017 Amendments in 2026 is sterilization.

CDSCO’s Gazette notification list records an August 2026 amendment introducing the Ninth Schedule and labelling requirements for sterilization activities. 

Sterilization is particularly important for medical devices where sterility is part of the intended use or regulatory specification.

Companies Should Review

Manufacturers and other relevant stakeholders should review:

• Sterilization procedures
• Validation documentation
• Labelling information
• Sterilization records
• Quality-control procedures
• Outsourced sterilization arrangements
• Relevant technical documentation

CDSCO had also previously issued guidance concerning the outsourcing of sterilization activities under MDR 2017, showing the importance of maintaining appropriate regulatory controls around such activities. 

3. Changes Relating to Medical Device Testing Fees

Testing is another area affected by 2026 regulatory developments.

CDSCO’s official notifications include a 10 April 2026 draft notification concerning amendments related to medical-device testing fees under MDR 2017. 

A draft notification is different from a final amendment, so companies should distinguish between proposed changes and requirements that have actually come into force.

Why Testing Fees Matter

Testing can be an important part of the regulatory process, particularly where a device requires assessment by an appropriate testing laboratory.

Companies should therefore monitor the latest CDSCO notification before budgeting for regulatory testing or finalising their compliance plan.

4. Risk Classification Remains a Critical Compliance Step

Risk classification continues to be an important part of medical-device regulation under MDR 2017.

CDSCO has published risk-based classification information and has also issued notices concerning updates to classification lists. In 2025, CDSCO published draft updates covering categories including cardiovascular and neurological devices, while other classification updates covered areas such as interventional radiology, radiotherapy and oncology.

Why Classification Matters

The classification of a medical device can influence the applicable regulatory pathway.

Medical devices are generally classified according to risk into:

• Class A – Low Risk
• Class B – Low-Moderate Risk
• Class C – Moderate-High Risk
• Class D – High Risk

Companies should identify the applicable classification before deciding which regulatory application or licence may be required.

5. Manufacturers Should Review Existing Compliance Documents

The MDR 2017 Amendments in 2026 make document review particularly important.

Manufacturers should consider reviewing:

• Device specifications
• Product descriptions
• Risk-management documentation
• Quality Management System records
• Manufacturing information
• Testing reports
• Sterilization documentation
• Labelling and packaging
• Clinical or performance information, where applicable
• Post-market surveillance records
• Existing CDSCO licences

The exact documentation required will depend on the device and regulatory pathway.

6. Importers and Foreign Manufacturers Should Monitor Changes

The MDR 2017 Amendments in 2026 are not relevant only to Indian manufacturers.

Importers and foreign medical-device companies entering the Indian market may also need to monitor changes that affect:

• Import licensing
• Authorised-agent arrangements
• Product documentation
• Manufacturer information
• Labelling
• Testing
• Quality documentation
• Post-market obligations

For imported devices, the regulatory strategy should be planned according to the applicable CDSCO requirements rather than treating import registration as a simple document-submission exercise.

7. Companies Should Monitor Draft and Final Notifications Separately

One of the most important practical points regarding the MDR 2017 Amendments in 2026 is understanding the difference between a draft notification and a final notification.

During 2026, CDSCO’s official notification database has included both draft and final MDR-related notifications. For example, draft notifications were published in April and June 2026, followed by final amendments in August 2026. 

Therefore, companies should verify:

1. Whether a notification is a draft or final rule.
2. The date of publication.
3. The effective date.
4. The specific MDR provision affected.
5. Whether transitional provisions apply.
6. Whether the amendment applies to the company’s particular device or activity.

How MDR 2017 Amendments in 2026 May Affect Medical Device Manufacturers

Manufacturers should consider performing a regulatory gap assessment.

Manufacturing

Review whether manufacturing procedures continue to meet the applicable MDR 2017 requirements.

Quality Management

Review QMS documentation and applicable quality procedures, particularly where an amendment specifically affects the relevant device category.

Labelling

Check whether product labels, packaging, and instructions require updates.

Sterilization

For sterile devices, verify that sterilization activities and associated documentation comply with applicable requirements.

Testing

Review testing plans and applicable laboratory requirements before beginning a new regulatory submission.

Regulatory Documentation

Keep regulatory files updated with the latest applicable requirements.

Impact on Medical Device Importers

Importers should also monitor the MDR 2017 Amendments in 2026 because changes affecting product documentation, labelling, testing or manufacturer information may have practical implications for imported products.

An importer should maintain appropriate records relating to:

• Foreign manufacturer
• Indian authorised agent
• Product details
• Import licence
• Product classification
• Labels
• Packaging
• Technical documents
• Testing information
• Complaints and adverse events

The exact obligations depend on the applicable device and regulatory framework.

Documents Medical Device Companies Should Review

Before applying for or updating a CDSCO licence, companies can review the following:

How to Prepare for MDR 2017 Amendments in 2026

A practical compliance approach can include the following steps.

Step 1: Identify Your Medical Device

Clearly define the device, intended purpose, and applicable product category.

Step 2: Confirm Risk Classification

Check the applicable CDSCO classification information and MDR 2017 classification rules.

Step 3: Review the Latest CDSCO Notifications

Check whether amendments or regulatory notices apply to your device.

Step 4: Conduct a Documentation Gap Review

Compare your existing documents against the latest applicable requirements.

Step 5: Review Labelling and Packaging

Check whether any applicable amendment affects your product label or packaging.

Step 6: Review QMS and Manufacturing Procedures

Ensure relevant internal procedures reflect the current regulatory requirements.

Step 7: Check Testing Requirements

Confirm whether additional testing or updated testing information is applicable.

Step 8: Maintain Regulatory Records

Keep evidence of compliance and regulatory decisions properly documented.

Common Mistakes Companies Should Avoid

Medical-device companies should avoid:

• Using outdated MDR information
• Confusing draft notifications with final amendments
• Selecting the wrong device classification
• Submitting incomplete technical documents
• Ignoring labelling requirements
• Failing to review sterilization documentation
• Assuming Class A devices have no compliance obligations
• Using outdated application information
• Not monitoring CDSCO notifications
• Treating regulatory compliance as a one-time activity

Regular regulatory monitoring can help companies identify changes before they become a problem for an application or existing compliance programme.

How ELT Corporate Helps with MDR 2017 Compliance

ELT Corporate assists medical-device businesses with regulatory and compliance requirements related to the Indian medical-device market.

Our support can include:

• Medical Device Registration
• CDSCO regulatory documentation
• Medical device risk classification support
• Manufacturing licence assistance
• Import licence assistance
• Regulatory documentation review
• Compliance-gap assessment
• Technical documentation support
• Application preparation
• Post-registration compliance guidance

Every medical device has its own regulatory requirements. Therefore, the applicable pathway should be assessed based on the device, intended use, classification, manufacturing/import activity and current CDSCO requirements.

For businesses affected by the MDR 2017 Amendments in 2026, a regulatory review can help identify which changes are relevant to their specific operations.

Conclusion

The MDR 2017 Amendments in 2026 represent an important area for medical-device companies to monitor. Recent CDSCO developments have addressed areas including quality management systems, sterilization, labelling, testing, and other regulatory requirements. 

Medical-device manufacturers, importers and foreign companies should regularly review official CDSCO notifications instead of relying only on older regulatory information.

Keeping product classification, technical documents, QMS records, testing information, sterilization documentation and labelling up to date can help businesses maintain their regulatory preparedness.

For the latest requirements, companies should always verify the applicable MDR 2017 provisions and final CDSCO notifications for their particular medical device.

10 Frequently Asked Questions About MDR 2017 Amendments in 2026

Q1. What are the MDR 2017 Amendments in 2026?

The MDR 2017 Amendments in 2026 include amendments and regulatory developments issued during 2026 concerning different provisions of the Medical Devices Rules, 2017. These developments include areas such as QMS, sterilization, and labelling requirements.

Q2. Why are MDR 2017 Amendments in 2026 important for manufacturers?

They may affect manufacturing, quality management, documentation, sterilization, labelling, and other compliance activities depending on the medical device and applicable provisions.

Q3. Did CDSCO introduce new medical device requirements in 2026?

Yes. CDSCO’s 2026 notification records include several MDR-related amendments and draft notifications concerning areas such as sterilization, labelling, QMS, and testing. 

Q4. Do the 2026 amendments apply to all medical devices?

Not necessarily. The applicability depends on the specific amendment, medical device, risk classification and activity involved.

Q5. Are Class A medical devices affected by MDR 2017 changes?

Certain Class A medical devices can be subject to specific regulatory requirements. The August 2026 amendment, for example, addressed QMS requirements in relation to Class A non-sterile and non-measuring devices under the relevant provision. 

Q6. Do the 2026 changes affect medical device labelling?

Certain 2026 amendments address labelling requirements associated with sterilization activities. Companies should check the applicable final notification for their device. 

Q7. Do MDR 2017 Amendments in 2026 affect medical device testing?

Testing-related amendments were proposed through a 2026 draft notification, and companies should check the current final requirements before planning testing or calculating applicable fees. 

Q8. How can I check the latest MDR 2017 requirements?

The latest requirements can be checked through the official CDSCO Medical Devices Rules, notifications and medical-device regulatory pages.

Q9. Do importers need to monitor MDR 2017 amendments?

Yes. Importers and foreign manufacturers should monitor applicable regulatory changes concerning their products, documentation, labelling, testing and import-related compliance.

Q10. Can ELT Corporate help with CDSCO medical device compliance?

Yes. ELT Corporate can assist businesses with medical-device registration, CDSCO documentation, licensing and regulatory compliance support based on the applicable requirements for their products.